Wave Life Sciences(WVE.US)盘前续涨近10% 昨日飙升147%

Core Viewpoint - Wave Life Sciences' obesity candidate drug WVE-007 shows promising mid-stage results from its Phase I INLIGHT trial, leading to a significant stock price increase [1] Group 1: Trial Results - The Phase I INLIGHT trial involved 32 subjects who received a single 240mg subcutaneous injection of WVE-007 [1] - After 12 weeks, visceral fat decreased by 9.4% (p=0.02), total body fat reduced by 4.5%, and lean body mass increased by 3.2% (approximately 4 pounds) [1] - Overall weight decreased by only 0.9% due to muscle gain offsetting fat loss [1] Group 2: Drug Efficacy - Serum Activin E levels reached a maximum suppression of 78% at 43 days post-injection, with efficacy maintained for over 85 days [1] - The results support the potential for annual or biannual dosing of WVE-007 [1]